Resistin, a newly discovered protein, promotes endothelial dysfunction and proinflammatory activation, contributing to subclinical atherosclerosis in different clinical settings. In this study we sought to investigate the relationship of increased resistin levels with estimated glomerular filtration rate (eGFR), the most established marker of kidney impairment, in hypertensive subjects. Our population consisted of 132 untreated non-diabetic subjects with stage I-II essential hypertension (49 males, mean age ¼ 54 years, office blood pressure (BP) ¼ 159/100 mm Hg). In all patients eGFR was assessed by the Modification in Renal Disease equation and venous blood sampling was performed for estimation of resistin concentrations. The distribution of resistin was split by the median (4.63 ng ml À1 ) and accordingly subjects were stratified into those with high and low values. In essential hypertensive subjects, higher resistin levels are associated with renal function impairment, as reflected by decreased eGFR. Moreover, the independent association of resistin with eGFR suggests involvement of resistin in the progression of kidney damage in the early stages of hypertension.
Introduction
Nowadays, increasing attention is paid to resistin, a newly discovered protein, that belongs to a family of polypeptides mainly produced by adipose tissuerelated leucocytes and mononuclear cells. [1] [2] [3] Although the pathophysiological role of resistin remains obscure in the setting of human cardiovascular diseases, accumulating evidence support that it promotes endothelial dysfunction and proinflammatory activation, leading to acceleration of subclinical atherosclerosis. [4] [5] [6] [7] [8] In these lines, augmented levels of resistin characterize patients with abdominal obesity, 9 type 2 diabetes mellitus 10 as well as essential hypertension 11, 12 suggesting involvement of this protein in multiple vascular disease states.
The recently reported associations of resistin with carotid atherosclerosis 13 and markers of chronic kidney impairment in patients with diverse levels of renal failure and dysmetabolic phenotype support an active role of resistin in the manifestation of diffuse atherosclerotic damage. [8] [9] [10] [11] [12] [13] [14] However, the data regarding the link between resistin and estimated glomerular filtration rate (eGFR), the established index of kidney damage, in hypertension remain rather scarce, 15 limiting our insight into the atherosclerotic effects of resistin in the hypertensive substrate.
On the basis of the above, the aim of this study was to explore the possible interrelationship of resistin levels with eGFR in non-diabetic subjects with untreated essential hypertension and to assess whether hyperresistinemia is accompanied by decreased eGFR in the same setting
Materials and methods

Study participants
The study population consisted of 210 consecutive subjects with untreated newly diagnosed (within the last 2 years) stage I-II essential hypertension who referred or self-referred to the outpatient hypertension unit within a period of 24 months. 16 Diagnosis of hypertension was based on three outpatient measures of blood pressure (BP) 4140/90 mm Hg and confirmed by daytime ambulatory BP 4135/ 85 mm Hg. All subjects underwent the usual clinical and laboratory work up to rule out secondary forms of hypertension. 16 Exclusion criteria included atherosclerotic cardiovascular and valvular disease, diabetes mellitus or impaired glucose tolerance, familial dyslipidemia, augmented serum creatinine concentration, overt proteinuria, eGFRo60 ml min À1 per 1.73 m 2 and any other clinically significant concurrent systemic disease. Moreover, none of the participants had any history or clinical/laboratory evidence of recent infection, inflammation, or underwent any medical treatment 1 month before entry in the study. Finally, by applying the exclusion criteria, 132 essential hypertensive subjects were selected for participation. The patients were studied supine, having fasted and abstained from smoking, alcohol and caffeinated beverages in the 12 h before the study. The study protocol included ambulatory BP monitoring, echocardiographic examination, anthropometric and metabolic determinations, as well as resistin levels estimation. The study protocol complies with the Declaration of Helsinki, was approved by our institutional ethics committee and all participants gave written informed consent.
Procedures
Office and ambulatory BP measurement. Office BP measurement was performed at three different visits in our outpatient clinic, according to guidelines. 16 Ambulatory BP was recorded over a working day (Monday through Friday) using the automatic Spacelabs units 90 207 (Redmond, WA, USA). The procedure has been described in detail. 17 In brief, the cuff was fixed to the non-dominant arm and the device was set to obtain automatic heart rate and BP readings at 15 min intervals during the daytime and at 30 min intervals during the night-time. In keeping with current practice, daytime and night-time were defined using short fixed-clock time intervals, which ranged from 1000 hours to 2000 hours and from midnight to 0600 hours, respectively. Twentyfour-hour systolic and diastolic BP values were the mean of the overall 24-h recordings after artefact editing.
Laboratory parameters determination. Venous blood sampling was performed from the anticubital fossa between 0800 hours and 0900 hours for the estimation of lipids, fasting glucose, serum creatinine and resistin concentrations. Levels of resistin were assessed using a commercially available solidphase sandwich ELISA kit (BioVendor) with intraand interassay coefficients of variation of 8.9 and 4.9%, respectively. Moreover, eGFR was calculated using the abbreviated equation from the Modification of Diet in Renal Disease Study (eGFR (ml min
À0.203 Â (0.742 if female)), using serum creatinine values. 18 Cardiac ultrasonography. The echocardiographic studies were performed by an experienced senior echocardiographer who was blind to the clinical status of the examined subject, using a General Electric Medical Systems Vivid 3 ultrasound imager equipped with a 2.25-5-MHz transducer, according to the recommendations of the American Society of Echocadiography. 19 Statistical analysis SPSS statistical package, release 12.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. Because of the skewed distribution, resistin and eGFR were logarithmically (log 10 ) transformed before statistical testing. The power analysis showed that the number of participants (n ¼ 132) was adequate to evaluate two-sided mean differences of 40.5 between subgroups and the investigated variables and could achieve statistical power 40.90 at the 5% probability level (P value).
Significant differences between the study subgroups were determined using the Student's independent-samples t-test or the w 2 -test, where appropriate. Correlation analyses were performed using the Pearson's correlation coefficient. Stepwise linear regression models were used to examine the independent predictors of eGFR. Analysis of covariance was performed to detect significant differences in eGFR between study subgroups after adjustment for potential confounders.
Descriptive statistics were arithmetic mean±s.d. All statistical assumptions were met and no multicollinearity problems were found to exist in our analyses. Statistical significance was set at Po0.05.
Results
According to the median value of resistin distribution (4.63 ng ml À1 ), hypertensive patients were divided into those with low (n ¼ 66) and high (n ¼ 66) values. Patients with high resistin compared to those with low resistin values had greater body mass index (by 2.1 kg/m 2 , P ¼ 0.008), whereas there was no difference in age, sex, smoking status and waist circumference (P ¼ NS for all). Moreover, hypertensive subjects with high resistin levels compared to those with low resistin exhibited no statistically significant differences regarding office and ambulatory BP readings (Table 1) Regarding renal function parameters, hypertensive subjects with high resistin compared to those with low resistin levels had higher serum creatinine (by 0.07 mg per 100 ml, P ¼ 0.018), urea (by 7.1 mg per 100 ml, P ¼ 0.001), although they exhibited lower eGFR values (by 12 ml min À1 per 1.73m 2 , Po0.0001; Figure 1 ; Table 2 ). Additionally, haematocrit, glucose and metabolic profile did not differ statistically between the two study groups (P ¼ NS for all; Table 2 ). Analysis of covariance revealed that the abovementioned difference in eGFR levels between groups remained statistically significant even after adjustment for age, sex, body mass index, waist circumference, smoking status, 24-h systolic/ diastolic BP, glucose and lipid levels (Po0.05).
In the total population, resistin exhibited a positive association with age (r ¼ 0.245, P ¼ 0.02), body mass index (r ¼ 0.369, P ¼ 0.001), waist circumference (r ¼ 0.203, P ¼ 0.006), 24-h systolic BP (r ¼ 0.244, Po0.05), 24-h heart rate (r ¼ 0.252, P ¼ 0.24), serum creatinine (r ¼ 0.311, P ¼ 0.007) and urea (r ¼ 0.348, P ¼ 0.003), whereas it was negatively correlated to eGFR (r ¼ À0.519, Po0.0001; Figure 2 ). When we split the entire population according to sex, the relationship of resistin with eGFR (r ¼
In a stepwise regression analysis model, using log eGFR as the dependent variable and age, sex, smoking status, body mass index, waist circumference, 24-h systolic/diastolic BP, 24-h heart rate, glucose, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and log resistin as the independent variables, it was revealed that age, body mass index, 24-h systolic BP and log resistin were the independent predictors of eGFR (Table 3) .
Discussion
The salient finding of our study is that circulating resistin is independently related with eGFR, the most established index of kidney dysfunction, in the early stages of essential hypertension. Moreover, hypertensive subjects with higher resistin levels are characterized by lower eGFR values, even after adjustment for demographic and metabolic confounders. These findings indicate that augmented levels of resistin may be a risk factor for renal disease or can be considered an alternative index of kidney dysfunction in hypertensive subjects. This is the first study to our knowledge that specifically addressed the issue of the relation of resistin with eGFR in a selective population of untreated non-diabetic hypertensive subjects of both genders. More specifically, resistin was responsible for 12% of eGFR variance. This finding extends the settings into which the association between resistin and eGFR is observed, such as chronic kidney disease, type 2 diabetes and coronary heart disease. 8, 20, 21 Reduced eGFR in hypertensive subjects can be considered a consequence of preglomerular microvasculopathy. 22, 23 In this context, resistin augments the expression of endothelin, adhesion molecules, matrix metalloproteinases, promoting systemic vascular dysfunction, unfavourably affecting eGFR. 2, 3, 7 Taking this notion further, eGFR might be an expression of exposure of kidney structures to both elevation BP and resistin-mediated vascular com- Figure 1 Box-and-whisker plot illustrating the distribution of eGFR in hypertensive subjects with low and high resistin levels. eGFR ¼ estimated glomerular filtration rate).
promise even in the early stages of atherosclerotic hypertensive disease. From another point of view, as the kidneys play an important role in the catabolism of small polypeptides such as resistin, a blunt in functional renal parenchyma could augment resistin concentrations. 15, 24 The role of haemodynamic load should also be stressed out because it constitutes a main correlate of both resistin and eGFR. [10] [11] [12] [13] [14] [15] 22 In our study, 24-h systolic BP was related to resistin and was an independent prognosticator of eGFR along with resistin. This suggests that hypertension-related intrarenal haemodynamic abnormalities lead to kidney dysfunction that might be further deteriorated by increased resistin. A growing amount of data support the interrelationship of eGFR with inflammatory involvement as well as a distinct role of low-grade inflammation in the progression of chronic kidney disease 3,9,14,15 and diffuse atherosclerosis reflected by microalbuminuria. 25, 26 In these lines, although resistin mediates diverse biological effects of cytokines, [27] [28] [29] there was a lack of association between resistin and white blood cell count in our population, a finding that is in contrast with previous reports. 6, 28 It should be noted that other more sensitive markers of subclinical inflammation such as C-reactive protein were not estimated in this study, thus the link between hyperresistinemia and inflammation may be missed. Nevertheless, as others have suggested the association of resistin with eGFR is unlikely to be mediated entirely through inflammatory activation. 15 As shown previously, 5, 15 resistin was related to age and body mass index, but in our setting, it predicted eGFR independently of these two atherosclerotic parameters. It is of note that in combination, age and body mass explained approximately 20% of eGFR levels, underscoring the unfavourable effect of ageing and excess adiposity on renal function in hypertension. Based on the above one could support that the interrelationship of hyperrestinemia with renal impairment is beyond the impact of cardiovascular ageing and obesity-related atherosclerotic damage. Nevertheless, these insightful theories must be further investigated in properly designed studies.
Limitations
This study is cross-sectional, therefore, the cause cannot be determined for any of the observed relationships. Additional limitations are the only once measured resistin levels taking into account that this protein might exhibit diurnal and intrain- dividual fluctuations and the fact that different isoforms of resistin, which could differ in their biological activities were not estimated. Moreover, GFR was not directly measured, thus the estimated associations with the other study parameters may be weakened. The fact that there are no available data on albuminuria partially limits the pathophysiological insight into the relationships of resistin with renal dysfunction and diffuse atherosclerosis in this setting. Our sample was also rather selective, consisting of middle-aged and non-diabetic patients, which attenuates the ability to generalize the findings to younger or older patients with different vascular disease burden. Nevertheless, potential strengths of the study are that all patients were untreated and ambulatory BP measurements were performed, given the insufficient precision of the sphygmomanometre compared to ambulatory monitoring. 30 Perspectives Based on our findings, although resistin determination could not be recommended in the routine evaluation of hypertensive subjects, further assessment of target organ damage maybe warranted and more aggressive therapeutic approach should be applied in those with augmented resistin levels. Moreover, the fact that resistin emerged as a potent predictor of eGFR, independently of haemodynamic and metabolic confounders, supports that this protein can be considered a candidate marker for cardiorenal risk determination and a novel target for intervention in hypertension.
In conclusion, hypertensive subjects with augmented resistin levels exhibit impaired eGFR, independently of established atherosclerotic risk factors. Moreover, the close association of resistin with eGFR suggests involvement of resistin in the progression of kidney damage in the early stages of essential hypertension.
